Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bicycle TherapeuticsFRA:50BA +2.44%53 Debt-to-Equity is 0.03 as of Jun. 2026, which is 63% below its 10-year median of 0.08. GuruFocus rates FRA:50BA with a GF Score™ of 53/100 and a GF Value™ of €12.66 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 971 Biotechnology companies, Bicycle Therapeutics ranks better than 80.74% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bicycle Therapeutics's Debt-to-Equity or its related term are showing as below:
FRA:50BA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.08 Max: 0.23
Current: 0.03
During the past 9 years, the highest Debt-to-Equity Ratio of Bicycle Therapeutics was 0.23. The lowest was 0.01. And the median was 0.08.
FRA:50BA's Debt-to-Equity is ranked better than 80.74% of 971
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:50BA: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Bicycle Therapeutics Debt-to-Equity Related Terms
Bicycle Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Bicycle Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:50BA vs CYDY, ALXO, SABS: Debt-to-Equity Comparison
For the Biotechnology subindustry, Bicycle Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicycle Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bicycle Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bicycle Therapeutics (FRA:50BA) has a Debt-to-Equity of 0.03 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bicycle Therapeutics and its competitors. This is 63% below median its historical median of 0.08. Over the past decade, Bicycle Therapeutics' Debt-to-Equity has ranged from 0.01 to 0.23. According to the industry distribution chart, Bicycle Therapeutics ranks #187 out of 971 companies in the Biotechnology industry, placing it in the top 19.3%.
Is Bicycle Therapeutics' Debt-to-Equity too high?
Bicycle Therapeutics' current Debt-to-Equity of 0.03 is 63% below median its 10-year median of 0.08. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.23. The Biotechnology industry median Debt-to-Equity is 0.16. Bicycle Therapeutics' value of 0.03 is 81.3% below this industry median. Based on the distribution chart, Bicycle Therapeutics ranks #187 out of 971 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bicycle Therapeutics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' Debt-to-Equity compare to CYDY and ALXO?
According to the Biotechnology industry distribution chart, Bicycle Therapeutics ranks #187 out of 971 companies for Debt-to-Equity. This places Bicycle Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Bicycle Therapeutics' value of 0.03 is 81.3% below this benchmark. Historically, Bicycle Therapeutics' own Debt-to-Equity has ranged from 0.01 to 0.23 over the past decade. While the company's 10-year median is 0.08 vs. the industry median of 0.16, Bicycle Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bicycle Therapeutics's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bicycle Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicycle Therapeutics's current Debt-to-Equity is 0.03, which is 63% below median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (FRA:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €12.66, compared to a current price of €3.36 — trading 73.5% below its estimated fair value. The current Debt-to-Equity is 0.03, which is 63% below median its 10-year median of 0.08 and 81.3% below the Biotechnology industry median of 0.16. Bicycle Therapeutics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bicycle Therapeutics (FRA:50BA), the current Debt-to-Equity is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?
Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued.
The current stock price of €3.36 is trading 73.5% below its estimated GF Value™ of €12.66.
GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:50BA:
Debt-to-Equity: 0.03 (63% below median its 10-year median of 0.08)
GF Value™: €12.66 vs. price of €3.36 (73.5% below fair value)
Industry Position: 81.3% below the Biotechnology median (#187 of 971)
No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
53GF Score
Get the complete analysis for FRA:50BA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:50BA has been successfully added to your 
